GW Pharma's Epidiolex Cited in Study Published in the New England Journal of Medicine

gwg-interviewThe stratospheric rise of medical marijuana as a possible recognized treatment for epilepsy, now underway, is an example of what can be achieved through the sharing of personal stories on the Internet and social media, according to a leading expert in the field.

Daniel Friedman, MD, New York University (NYU) Langone School of Medicine, is a coauthor a review article, “Cannabinoids in the Treatment of Epilepsy,” published in the September 10 issue of The New England Journal of Medicine.

“It’s very much ‘watch this space’ at the moment,” Dr Friedman commented to Medscape Medical News. “There is emerging evidence on efficacy. The preclinical evidence is reasonably strong for cannabidiol, similar to that for a new pharmaceutical for epilepsy. The clinical data are still early. So far the studies have been small and methodologically flawed, but results are encouraging.”

Read “Stratospheric Rise of Medical Marijuana in Epilepsy” by Sue Hughes: http://www.medscape.com/viewarticle/850805

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter